# reload+after+2024-01-21 07:45:16.204602
address1§4242 Campus Point Court
address2§Suite 200
city§San Diego
state§CA
zip§92121
country§United States
phone§858 251 4400
website§https://www.herontx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
fullTimeEmployees§203
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Craig Alexander Collard', 'age': 57, 'title': 'CEO & Director', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ira  Duarte', 'age': 54, 'title': 'Executive VP & CFO', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lisa  Peraza', 'age': 46, 'title': 'VP & Chief Accounting Officer', 'yearBorn': 1977, 'fiscalYear': 2021, 'totalPay': 474102, 'exercisedValue': 0, 'unexercisedValue': 1393}, {'maxAge': 1, 'name': 'Dr. Thomas B. Ottoboni Ph.D.', 'age': 64, 'title': 'Chief Scientific Officer and Senior VP of Pharmaceutical & Translational Sciences', 'yearBorn': 1959, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan  Craig', 'title': 'Vice President of Marketing', 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sean T. Ristine', 'age': 53, 'title': 'Senior Vice President of Human Resources', 'yearBorn': 1970, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Chris M. Storgard', 'age': 57, 'title': 'Chief Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Sullivan', 'age': 45, 'title': 'Senior VP of Oncology Care Franchise & Commercial Operations', 'yearBorn': 1978, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. William P. Forbes Pharm. D., Pharm.D.', 'age': 61, 'title': 'Executive VP & Chief Development Officer', 'yearBorn': 1962, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Jeff  Cohn', 'title': 'Executive Director, Assistant General Counsel & Assistant Secretary', 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§3
compensationRisk§5
shareHolderRightsRisk§1
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1640908800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.63
priceToSalesTrailing12Months§2.1624174
currency§USD
dateShortInterest§1702598400
forwardEps§-0.38
pegRatio§-0.04
exchange§NCM
quoteType§EQUITY
shortName§Heron Therapeutics, Inc.
longName§Heron Therapeutics, Inc.
firstTradeDateEpochUtc§556983000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§806ac89f-8627-346c-9c83-0c9ea6a496d7
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§2.5
targetMeanPrice§5.63
targetMedianPrice§5.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§1.771
grossMargins§0.05689
ebitdaMargins§-0.77560997
trailingPegRatio§None
